PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated or positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with ...

Equine surgeon Dr. Larry Bramlage says the type and length of turnout a horse gets when healing makes a crucial difference ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

Dosimetry is integral to informed implementation of radiopharmaceutical therapies, enabling personalized treatment planning ...

The company notes that PSMA-PET imaging represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT6 scan) as the standard of care ...

https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/basics/lung-cancer-research ...

What is Driving the Growth of the Neurological Disorder Diagnostics Market?The global neurological disorder diagnostics market is experiencing significant growth, driven by the increasing prevalence ...

Ovarian Cancer Market Analysis & Forecast by Diagnosis 2023 - 2034 (Revenue USD Bn) U.S. About is the world's leading source for international market research reports and market data. We provide you ...

PEOPLE often think of Alzheimer’s when they think of dementia. It’s the most common type of dementia, accounting for 60-80 ...

Radiopharm Theranostics appears to be emerging from unloved status to that of a genuine contender in the red-hot ...

Telix Pharma’s prostate cancer PET1 imaging agent, Illuccix receives European marketing approval: Melbourne, Australia Saturday, January 18, 2025, 10:00 Hrs [IST] Telix Pharmace ...